|
1
|
Chabas D, Baranzini SE, Mitchell D,
Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M,
Pedotti R, et al: The influence of the proinflammatory cytokine,
osteopontin, on autoimmune demyelinating disease. Science.
294:1731–1735. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Icer MA and Gezmen-Karadag M: The multiple
functions and mechanisms of osteopontin. Clin Biochem. 59:17–24.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yim A, Smith C and Brown AM:
Osteopontin/secreted phosphoprotein-1 harnesses glial-, immune-,
and neuronal cell ligand-receptor interactions to sense and
regulate acute and chronic neuroinflammation. Immunol Rev.
311:224–233. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Klement JD, Paschall AV, Redd PS, Ibrahim
ML, Lu C, Yang D, Celis E, Abrams SI, Ozato K and Liu K: An
osteopontin/CD44 immune checkpoint controls CD8+ T cell activation
and tumor immune evasion. J Clin Invest. 128:5549–5560. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu C, Liu Z, Klement JD, Yang D, Merting
AD, Poschel D, Albers T, Waller JL, Shi H and Liu K: WDR5-H3K4me3
epigenetic axis regulates OPN expression to compensate PD-L1
function to promote pancreatic cancer immune escape. J Immunother
Cancer. 9:e0026242021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hui EP, Sung FL, Yu BK, Wong CS, Ma BB,
Lin X, Chan A, Wong WL and Chan AT: Plasma osteopontin, hypoxia,
and response to radiotherapy in nasopharyngeal cancer. Clin Cancer
Res. 14:7080–7087. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ,
Chen CJ, Chi NH, Chen GH and Lin JT: Elevated plasma osteopontin
associated with gastric cancer development, invasion and survival.
Gut. 56:782–789. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Blasberg JD, Pass HI, Goparaju CM, Flores
RM, Lee S and Donington JS: Reduction of elevated plasma
osteopontin levels with resection of non-small-cell lung cancer. J
Clin Oncol. 28:936–941. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qin X, Yan M, Wang X, Xu Q, Wang X, Zhu X,
Shi J, Li Z, Zhang J and Chen W: Cancer-associated
Fibroblast-derived IL-6 promotes head and neck cancer progression
via the osteopontin-NF-kappa B signaling pathway. Theranostics.
8:921–940. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Briones-Orta MA, Avendaño-Vázquez SE,
Aparicio-Bautista DI, Coombes JD, Weber GF and Syn WK: Osteopontin
splice variants and polymorphisms in cancer progression and
prognosis. Biochim Biophys Acta Rev Cancer. 1868:93–108.A. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang RH, Quan YJ, Chen JH, Wang TF, Xu M,
Ye M, Yuan H, Zhang CJ, Liu XJ and Min ZJ: Osteopontin promotes
cell migration and invasion, and inhibits apoptosis and autophagy
in colorectal cancer by activating the p38 MAPK signaling pathway.
Cell Physiol Biochem. 41:1851–1864. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu Q, Li L, Miao C, Hasnat M, Sun L, Jiang
Z and Zhang L: Osteopontin promotes hepatocellular carcinoma
progression through inducing JAK2/STAT3/NOX1-mediated ROS
production. Cell Death Dis. 13:3412022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao J, Dong L, Lu B, Wu G, Xu D, Chen J,
Li K, Tong X, Dai J, Yao S, et al: Down-regulation of osteopontin
suppresses growth and metastasis of hepatocellular carcinoma via
induction of apoptosis. Gastroenterology. 135:956–968. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shang S, Plymoth A, Ge S, Feng Z, Rosen
HR, Sangrajrang S, Hainaut P, Marrero JA and Beretta L:
Identification of osteopontin as a novel marker for early
hepatocellular carcinoma. Hepatology. 55:483–490. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haga Y, Kanda T, Nakamura M, Nakamoto S,
Sasaki R, Takahashi K, Wu S and Yokosuka O: Overexpression of c-Jun
contributes to sorafenib resistance in human hepatoma cell lines.
PLoS One. 12:e01741532017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Manna D, Reghupaty SC, Camarena MDC,
Mendoza RG, Subler MA, Koblinski JE, Martin R, Dozmorov MG,
Mukhopadhyay ND, Liu J, et al: Melanoma differentiation associated
gene-9/syndecan binding protein promotes hepatocellular carcinoma.
Hepatology. Sep 19–2022.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu X, Zheng Y, Zhu X, Gao X, Wang C, Sheng
Y, Cheng W, Qin L, Ren N, Jia H and Dong Q: Osteopontin promotes
hepatocellular carcinoma progression via the PI3K/AKT/Twist
signaling pathway. Oncol Lett. 16:5299–5308. 2018.PubMed/NCBI
|
|
18
|
Zhang R, Pan X, Huang Z, Weber GF and
Zhang G: Osteopontin enhances the expression and activity of MMP-2
via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines.
PLoS One. 6:e238312011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang G, Zhang S, Gao F, Liu Z, Lu M, Peng
S, Zhang T and Zhang F: Osteopontin enhances the expression of
HOTAIR in cancer cells via IRF1. Biochim Biophys Acta.
1839:837–848. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sansam CL, Shepard JL, Lai K, Ianari A,
Danielian PS, Amsterdam A, Hopkins N and Lees JA: DTL/CDT2 is
essential for both CDT1 regulation and the early G2/M checkpoint.
Genes Dev. 20:3117–3129. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feng M, Wang Y, Bi L, Zhang P, Wang H,
Zhao Z, Mao JH and Wei G: CRL4A(DTL) degrades DNA-PKcs to modulate
NHEJ repair and induce genomic instability and subsequent malignant
transformation. Oncogene. 40:2096–2111. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu YW, Cao LR, Wang M, Xu Y, Wu X, Liu J,
Tong C and Fan HY: Maternal DCAF2 is crucial for maintenance of
genome stability during the first cell cycle in mice. J Cell Sci.
130:3297–3307. 2017.PubMed/NCBI
|
|
23
|
Cui H, Wang Q, Lei Z, Feng M, Zhao Z, Wang
Y and Wei G: DTL promotes cancer progression by PDCD4
ubiquitin-dependent degradation. J Exp Clin Cancer Res. 38:3502019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu L, Xiao F, Yu Y, Wang H, Fang M, Yang
Y, Sun H, Wang L and Sheng Y: KSP inhibitor SB743921 inhibits
growth and induces apoptosis of breast cancer cells by regulating
p53, Bcl-2, and DTL. Anticancer Drugs. 27:863–872. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Xu X, Liu C, Xi X, Wang Y, Wu X and
Li H: MiR-490-5p restrains progression of Gastric cancer through
DTL repression. Gastroenterol Res Pract. 2021:28941172021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baraniskin A, Birkenkamp-Demtroder K,
Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick
A, Schwarte-Waldhoff I, Schmiegel W and Hahn SA: MiR-30a-5p
suppresses tumor growth in colon carcinoma by targeting DTL.
Carcinogenesis. 33:732–739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative pcr and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen YC, Chen IS, Huang GJ, Kang CH, Wang
KC, Tsao MJ and Pan HW: Targeting DTL induces cell cycle arrest and
senescence and suppresses cell growth and colony formation through
TPX2 inhibition in human hepatocellular carcinoma cells. Onco
Targets Ther. 11:1601–1616. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin YH and Yang-Yen HF: The
osteopontin-CD44 survival signal involves activation of the
phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem.
276:46024–46030. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Urtasun R, Lopategi A, George J, Leung TM,
Lu Y, Wang X, Ge X, Fiel MI and Nieto N: Osteopontin, an oxidant
stress sensitive cytokine, up-regulates collagen-I via integrin
α(V)β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology.
55:594–608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Le QT, Sutphin PD, Raychaudhuri S, Yu SC,
Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC and Giaccia AJ:
Identification of osteopontin as a prognostic plasma marker for
head and neck squamous cell carcinomas. Clin Cancer Res. 9:59–67.
2003.PubMed/NCBI
|
|
32
|
Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E,
Lee NP, Wu GH and Luk JM: Osteopontin as potential biomarker and
therapeutic target in gastric and liver cancers. World J
Gastroenterol. 18:3923–3930. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu M, Zheng J, Wu F, Kang B, Liang J,
Heskia F, Zhang X and Shan Y: OPN is a promising serological
biomarker for hepatocellular carcinoma diagnosis. J Med Virol.
92:3596–3603. 2020. View Article : Google Scholar
|
|
34
|
Qian J, LeSavage BL, Hubka KM, Ma C,
Natarajan S, Eggold JT, Xiao Y, Fuh KC, Krishnan V, Enejder A, et
al: Cancer-associated mesothelial cells promote ovarian cancer
chemoresistance through paracrine osteopontin signaling. J Clin
Invest. 131:e1461862021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bao Y, Wang L, Shi L, Yun F, Liu X, Chen
Y, Chen C, Ren Y and Jia Y: Transcriptome profiling revealed
multiple genes and ECM-receptor interaction pathways that may be
associated with breast cancer. Cell Mol Biol Lett. 24:382019.
View Article : Google Scholar : PubMed/NCBI
|
